Close Menu

PerkinElmer

There were fewer mergers and acquisitions in the omics space in 2017, breaking a two-year streak of growth — however, the deals themselves stayed fairly large.

The company beat analyst estimates on the top and bottom lines, and said sales from its diagnostics business rose 13 percent year over year.

The index gained more than 3 percent, significantly outperforming the Nasdaq Biotechnology Index, but slightly underperforming the Dow and Nasdaq.

The combined workflow will enable the analysis of archival dried blood spots using 10x Genomics' linked-read technology, according to the companies.

PerkinElmer Genetics will provide clinical whole-genome sequencing, data interpretation, and diagnostic reports to IDG for patients with neurological disorders.

Last week, the company launched whole-genome sequencing of children for customers of its ViaCord cord blood and tissue banking business.

The firm said it may use the loans to finance its $1.3 billion acquisition of Euroimmun Medical Laboratory Diagnostics.

The company also launched a clinical genomics service, offering newborn screening and high-throughput NSG for rare inherited diseases.

Euroimmun is a global leader in autoimmune testing and an emerging force in infectious disease and allergy testing, according to PerkinElmer.

PerkinElmer's subsidiary Wallac will now distribute the Amplidiag product line in Israel and in a number of countries in Africa.

Pages

A new study catalogues the genome and evolutionary history of the oak family, UPI reports.

Dog DNA testing is a growing market, but there's still a lot of uncertainty about the accuracy of the results, the Boston Globe says.

A University of South Florida researcher is testing bone fragments to determine if they belong to Amelia Earhart.

In Cell this week: antisense Piwi-interacting RNA responses to endogenous retroviruses, proteomic patterns in hepatocellular carcinoma, and more.